No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	decitabine Sensitive: A1 - Approval decitabine Sensitive : A1	decitabine Sensitive: A1 - Approval decitabine Sensitive : A1
No biomarker	Myelodysplastic Syndrome	No biomarker	Myelodysplastic Syndrome	decitabine Sensitive: A1 - Approval decitabine Sensitive : A1	decitabine Sensitive: A1 - Approval decitabine Sensitive : A1
TP53 mutation	Myelodysplastic Syndrome	TP53 mutation	Myelodysplastic Syndrome	decitabine Sensitive: C2 – Inclusion Criteria decitabine Sensitive : C2	decitabine Sensitive: C2 – Inclusion Criteria decitabine Sensitive : C2
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	decitabine Sensitive: C2 – Inclusion Criteria decitabine Sensitive : C2	decitabine Sensitive: C2 – Inclusion Criteria decitabine Sensitive : C2
DNMT3A mutation	Myelodysplastic Syndrome	DNMT3A mutation	Myelodysplastic Syndrome	decitabine Resistant: C3 – Early Trials decitabine Resistant : C3	decitabine Resistant: C3 – Early Trials decitabine Resistant : C3
U2AF1 mutation	Myelodysplastic Syndrome	U2AF1 mutation	Myelodysplastic Syndrome	decitabine Resistant: C3 – Early Trials decitabine Resistant : C3	decitabine Resistant: C3 – Early Trials decitabine Resistant : C3
NPM1 mutation	Myelodysplastic Syndrome	NPM1 mutation	Myelodysplastic Syndrome	decitabine Sensitive: C3 – Early Trials decitabine Sensitive : C3	decitabine Sensitive: C3 – Early Trials decitabine Sensitive : C3
KMT2A-PTD	Acute Myelogenous Leukemia	KMT2A-PTD	Acute Myelogenous Leukemia	cytarabine + decitabine + vorinostat Sensitive: C3 – Early Trials cytarabine + decitabine + vorinostat Sensitive : C3	cytarabine + decitabine + vorinostat Sensitive: C3 – Early Trials cytarabine + decitabine + vorinostat Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	decitabine + clofarabine Sensitive: C3 – Early Trials decitabine + clofarabine Sensitive : C3	decitabine + clofarabine Sensitive: C3 – Early Trials decitabine + clofarabine Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	decitabine + cladribine Sensitive: C3 – Early Trials decitabine + cladribine Sensitive : C3	decitabine + cladribine Sensitive: C3 – Early Trials decitabine + cladribine Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	decitabine + clofarabine Sensitive: C3 – Early Trials decitabine + clofarabine Sensitive : C3	decitabine + clofarabine Sensitive: C3 – Early Trials decitabine + clofarabine Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	decitabine + cladribine Sensitive: C3 – Early Trials decitabine + cladribine Sensitive : C3	decitabine + cladribine Sensitive: C3 – Early Trials decitabine + cladribine Sensitive : C3
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	decitabine + clofarabine Sensitive: C3 – Early Trials decitabine + clofarabine Sensitive : C3	decitabine + clofarabine Sensitive: C3 – Early Trials decitabine + clofarabine Sensitive : C3
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	decitabine + cladribine Sensitive: C3 – Early Trials decitabine + cladribine Sensitive : C3	decitabine + cladribine Sensitive: C3 – Early Trials decitabine + cladribine Sensitive : C3
RUNX1 mutation	Acute Myelogenous Leukemia	RUNX1 mutation	Acute Myelogenous Leukemia	decitabine + clofarabine Sensitive: C3 – Early Trials decitabine + clofarabine Sensitive : C3	decitabine + clofarabine Sensitive: C3 – Early Trials decitabine + clofarabine Sensitive : C3
RUNX1 mutation	Acute Myelogenous Leukemia	RUNX1 mutation	Acute Myelogenous Leukemia	decitabine + cladribine Sensitive: C3 – Early Trials decitabine + cladribine Sensitive : C3	decitabine + cladribine Sensitive: C3 – Early Trials decitabine + cladribine Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	FLT3 inhibitor + venetoclax + decitabine Sensitive: C3 – Early Trials FLT3 inhibitor + venetoclax + decitabine Sensitive : C3	FLT3 inhibitor + venetoclax + decitabine Sensitive: C3 – Early Trials FLT3 inhibitor + venetoclax + decitabine Sensitive : C3
NRAS mutation	Acute Myelogenous Leukemia	NRAS mutation	Acute Myelogenous Leukemia	decitabine Resistant: C3 – Early Trials decitabine Resistant : C3	decitabine Resistant: C3 – Early Trials decitabine Resistant : C3
TP53 mutation	Myelodysplastic Syndrome	TP53 mutation	Myelodysplastic Syndrome	decitabine + MBG453 Sensitive: C3 – Early Trials decitabine + MBG453 Sensitive : C3	decitabine + MBG453 Sensitive: C3 – Early Trials decitabine + MBG453 Sensitive : C3
WT1 overexpression	Myelodysplastic Syndrome	WT1 overexpression	Myelodysplastic Syndrome	cytarabine + decitabine + tretinoin Sensitive: C3 – Early Trials cytarabine + decitabine + tretinoin Sensitive : C3	cytarabine + decitabine + tretinoin Sensitive: C3 – Early Trials cytarabine + decitabine + tretinoin Sensitive : C3
TP53 mutation	Myelodysplastic Syndrome	TP53 mutation	Myelodysplastic Syndrome	cytarabine + decitabine + tretinoin Sensitive: C3 – Early Trials cytarabine + decitabine + tretinoin Sensitive : C3	cytarabine + decitabine + tretinoin Sensitive: C3 – Early Trials cytarabine + decitabine + tretinoin Sensitive : C3
ASXL1 mutation	Myelodysplastic Syndrome	ASXL1 mutation	Myelodysplastic Syndrome	cytarabine + decitabine + tretinoin Sensitive: C3 – Early Trials cytarabine + decitabine + tretinoin Sensitive : C3	cytarabine + decitabine + tretinoin Sensitive: C3 – Early Trials cytarabine + decitabine + tretinoin Sensitive : C3
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	decitabine Sensitive: C3 – Early Trials decitabine Sensitive : C3	decitabine Sensitive: C3 – Early Trials decitabine Sensitive : C3
Chr del(5q)	Acute Myelogenous Leukemia	Chr del(5q)	Acute Myelogenous Leukemia	cytarabine + decitabine + mitoxantrone Sensitive: C3 – Early Trials cytarabine + decitabine + mitoxantrone Sensitive : C3	cytarabine + decitabine + mitoxantrone Sensitive: C3 – Early Trials cytarabine + decitabine + mitoxantrone Sensitive : C3
TP53 mutation	Myelodysplastic Syndrome	TP53 mutation	Myelodysplastic Syndrome	etoposide IV + decitabine Sensitive: C3 – Early Trials etoposide IV + decitabine Sensitive : C3	etoposide IV + decitabine Sensitive: C3 – Early Trials etoposide IV + decitabine Sensitive : C3
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	etoposide IV + decitabine Sensitive: C3 – Early Trials etoposide IV + decitabine Sensitive : C3	etoposide IV + decitabine Sensitive: C3 – Early Trials etoposide IV + decitabine Sensitive : C3
KRAS mutation	Juvenile Myelomonocytic Leukemia	KRAS mutation	Juvenile Myelomonocytic Leukemia	decitabine Sensitive: C4 – Case Studies decitabine Sensitive : C4	decitabine Sensitive: C4 – Case Studies decitabine Sensitive : C4
PAN3-PSMA2 fusion	Myelodysplastic Syndrome	PAN3-PSMA2 fusion	Myelodysplastic Syndrome	decitabine Sensitive: C4 – Case Studies decitabine Sensitive : C4	decitabine Sensitive: C4 – Case Studies decitabine Sensitive : C4
DNMT3A overexpression	Gastric Cancer	DNMT3A overexpression	Gastric Cancer	decitabine Sensitive: D – Preclinical decitabine Sensitive : D	decitabine Sensitive: D – Preclinical decitabine Sensitive : D
IDH1 mutation + Chr del(1p) + Chr del(19q)	Glioma	IDH1 mutation + Chr del(1p) + Chr del(19q)	Glioma	decitabine Sensitive: D – Preclinical decitabine Sensitive : D	decitabine Sensitive: D – Preclinical decitabine Sensitive : D
SOCS1 overexpression	Hepatocellular Cancer	SOCS1 overexpression	Hepatocellular Cancer	decitabine Sensitive: D – Preclinical decitabine Sensitive : D	decitabine Sensitive: D – Preclinical decitabine Sensitive : D
GSTP1 overexpression	Hepatocellular Cancer	GSTP1 overexpression	Hepatocellular Cancer	decitabine Sensitive: D – Preclinical decitabine Sensitive : D	decitabine Sensitive: D – Preclinical decitabine Sensitive : D

decitabine

Associations
(40)

Associations
(40)

decitabine

Associations(40)

Associations(40)

Associations
(40)

Associations
(40)